Mary Jane Meegan

Title: Mary Jane Meegan: Innovator in Androgen Receptor Research

Introduction

Mary Jane Meegan is a distinguished inventor based in Ballinteer, Ireland. She has made significant contributions to the field of androgen receptor research, particularly in developing novel therapeutic strategies for androgen-dependent conditions. Her work is crucial in addressing the challenges faced in current prostate cancer treatments.

Latest Patents

Mary Jane Meegan holds a patent for "Androgen receptor ligands - Non ligand binding pocket antagonists for the human androgen receptor." This innovative patent focuses on a class of non-steroidal, small molecule AR antagonists that inhibit the transcriptional activity of the androgen receptor through non-ligand binding pocket-mediated modulation. The research highlights the potential of these antagonists as an alternative approach to classical prostate cancer therapy, demonstrating full antagonism with low micromolar potency and high selectivity over other receptors.

Career Highlights

Mary Jane Meegan is affiliated with the College of the Holy and Undivided Trinity of Queen Elizabeth, near Dublin. Her academic and research endeavors have positioned her as a leading figure in the study of androgen receptors and their implications in various medical conditions.

Collaborations

She has collaborated with notable colleagues, including David George Lloyd and Darren Fayne, contributing to the advancement of research in her field.

Conclusion

Mary Jane Meegan's innovative work in androgen receptor research exemplifies the importance of developing new therapeutic strategies for treating prostate cancer and other androgen-dependent conditions. Her contributions are paving the way for future advancements in medical treatments.